VENLO, Netherlands, June 18, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on ...

QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics ...

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership Provided by Business Wire Jun 18, 2025, 8:05:00 PM.

Qiagen and Gencurix have entered a partnership to develop cancer tests for clinical diagnostics. The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital ...

VENLO, Netherlands - QIAGEN (NYSE: QGEN), a $10 billion molecular diagnostics company with excellent financial health according to InvestingPro analysis, and GENCURIX (KOSDAQ: 229000) announced a ...

QIAGEN expanded the assay menu by launching more than 100 new digital PCR assays and is on track to add 100 more in 2025, now focusing on cell and gene therapy and pathogen research.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive ...

QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to ...

A month has gone by since the last earnings report for Qiagen (QGEN). Shares have added about 8.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...